# Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

> **NCT01258855** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 84 (actual)

## Conditions studied

- Metastatic Melanoma
- Recurrent Melanoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Ziv-Aflibercept

## Key facts

- **NCT ID:** NCT01258855
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-18
- **Primary completion:** 2018-03-29
- **Final completion:** 2018-03-29
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258855, "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01258855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*